


Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



wherein


m is an integer of from 0 to 3;

n is an integer of from 0 to 3;

R₁ is aryl;

R₂ is

- a) a group of the formula -N(R₉R₁₀), -NHC(O)R₉, or -NHC(O)OR₉;
- b) a group of the formula -OR₉;
- c) a group of the formula -SR₉, -SOR₉, -SO₂R₉, -SO₂NHR₉, or -SO₂N(R₉R₁₀);
wherein R₉ and R₁₀ are independently selected from the group consisting of
 - 1) -H;
 - 2) -Aryl;
 - 3) -C₁₋₆ alkyl;
 - 4) -C₁₋₆ alkylaryl; and



R₃ and R₄ are independently selected from the group consisting of

- a) H;
- b) -aryl;
- c) -C₁₋₆ alkyl;
- d) -C₁₋₆ alkylaryl; and
- e) -C₁₋₆ alkoxyaryl;


R₅, R₆, R₇, and R₈ are independently selected from the group consisting of

- a) -H;
- b) -C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl;
- e) -C(O)-O-C₁₋₆ alkyl;
- f) -C(O)-O-C₁₋₆ alkylaryl;
- g) -C(O)-NH-C₁₋₆ alkyl;
- h) -C(O)-NH-C₁₋₆ alkylaryl;
- i) -SO₂-C₁₋₆ alkyl;
- j) -SO₂-C₁₋₆ alkylaryl;
- k) -SO₂-aryl;
- l) -SO₂-NH-C₁₋₆ alkyl;
- m) -SO₂-NH-C₁₋₆ alkylaryl;
- n) -C(O)-C₁₋₆ alkyl;
- o) -C(O)-C₁₋₆ alkylaryl;
- p) -Y-C₁₋₆ alkyl;
- q) -Y-aryl;
- r) -Y-C₁₋₆ alkylaryl;

s) $-Y-C_{1-6}$ alkylene- $NR_{13}R_{14}$;

t) $-Y-C_{1-6}$ alkylene-W- R_{15} ;

wherein Y and W are independently selected from the group consisting of $-CH_2-$, $-O-$, $-N(H)-$, $-S-$, SO_2- , $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-NHSO_2NH-$, $-O-CO-$,



wherein R_{16} and R_{17} are independently selected from the group consisting of aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;


R_{15} is aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl; and

u) halogen, hydroxyl, cyano, carbamoyl, and carboxyl;

wherein at least one of R_5 , R_6 , R_7 , and R_8 is $-Y-C_{1-6}$ alkylene- $NR_{13}R_{14}$, and

R_{11} , R_{12} , R_{13} , and R_{14} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; or


R_{13} and R_{14} are taken together to form a ring having the formula $-(CH_2)_o-X-(CH_2)_p-$ bonded to the nitrogen atom to which R_{13} and R_{14} are attached, and/or R_{11} and R_{12} are taken together to form a ring having the formula $-(CH_2)_o-X-(CH_2)_p-$ bonded to the atoms to which R_{11} and R_{12} are connected, wherein o and p are, independently, 1, 2, 3, or 4; X is a direct bond, $-CH_2-$, $-O-$, $-S-$, $-S(O_2)-$, $-C(O)-$, $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-O-C(O)-$, $-NHSO_2NH-$,



wherein the aryl and/or alkyl group(s) in R_1 , R_2 , R_3 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , R_{18} , and R_{19} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups selected from the group consisting of:

- a) -H;
- b) -Z-C₁₋₆ alkyl;
 -Z-aryl;
 -Z-C₁₋₆ alkylaryl;
 -Z-C₁₋₆-alkyl-NR₂₀R₂₁;
 -Z-C₁₋₆-alkyl-W-R₂₂;

wherein Z and W are independently selected from the group consisting of -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,




wherein;

R_{22} , R_{23} , and R_{24} are independently selected from the group consisting of aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl;

- c) halogen, hydroxyl, cyano, and carbamoyl, ~~and carboxyl~~; and


wherein R_{20} and R_{21} are independently selected from the group consisting of hydrogen, aryl, C_1 - C_6 alkyl, C_1 - C_6 alkylaryl, C_1 - C_6 alkoxy, and C_1 - C_6 alkoxyaryl; or

R_{20} and R_{21} are taken together to form a ring having the formula $-(CH_2)_q-X-(CH_2)_r-$ bonded to the nitrogen atom to which R_{20} and R_{21} are attached wherein q and r are, independently, 1, 2, 3, or 4; X is a direct bond, $-CH_2-$, $-O-$, $-S-$, $-S(O_2)-$, $-C(O)-$, $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-O-C(O)-$, $-NHSO_2NH-$,



R_{25} , R_{26} , and R_{27} are independently selected from the group consisting of hydrogen, aryl, C_1 - C_6 alkyl, and C_1 - C_6 alkylaryl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

2. (Currently Amended) The compound of claim 1, wherein m is an integer of from 0 to 3; n is 0; R_3 is hydrogen as represented by the formula (II)



and wherein

R_1 is an aryl group;

R₂ is a group of the formula -N(R₉R₁₀), -NHC(O)R₉, or -NHC(O)OR₉;

wherein R₉ and R₁₀ are independently selected from the group consisting of

- 1) -H;
- 2) -Aryl;
- 3) -C₁₋₆ alkyl; and
- 4) -C₁₋₆ alkylaryl;

R₄ is


- a) H;
- b) -aryl;
- c) -C₁₋₆ alkyl;
- d) -C₁₋₆ alkylaryl; or
- e) -C₁₋₆ alkoxyaryl;

R₅, R₆, R₇, and R₈ are independently selected from the group consisting of

- a) -H;
- b) -C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl;
- e) -C(O)-O-C₁₋₆ alkyl;
- f) -C(O)-O-C₁₋₆ alkylaryl;
- g) -C(O)-NH-C₁₋₆ alkyl;
- h) -C(O)-NH-C₁₋₆ alkylaryl;
- i) -SO₂-C₁₋₆ alkyl;
- j) -SO₂-C₁₋₆ alkylaryl;
- k) -SO₂-aryl;
- l) -SO₂-NH-C₁₋₆ alkyl;
- m) -SO₂-NH-C₁₋₆ alkylaryl;
- n) -C(O)-C₁₋₆ alkyl;
- o) -C(O)-C₁₋₆ alkylaryl;
- p) -Y-C₁₋₆ alkyl;

- q) -Y-aryl;
 r) -Y-C₁₋₆ alkylaryl;
 s) -Y-C₁₋₆ alkylene-NR₁₃R₁₄;
 t) -Y-C₁₋₆ alkylene-W-R₁₅;

wherein Y and W are independently selected from the group consisting of -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,



wherein R₁₆ and R₁₇ are independently selected from the group consisting of aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl;


R₁₅ is aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl, and

- u) halogen, hydroxyl, cyano, carbamoyl, and carboxyl;

wherein at least one of R₅, R₆, R₇, and R₈ is -Y-C₁₋₆ alkylene-N-R₁₃R₁₄,

R₁₃, and R₁₄ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl; or


R₁₃ and R₁₄ are together to form a ring having the formula -(CH₂)_o-X-(CH₂)_p- bonded to the nitrogen atom to which R₁₃ and R₁₄ are attached, wherein o and p are, independently, 1, 2, 3, or 4; X is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHCO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHCO₂NH-,



and wherein the aryl and/or alkyl group(s) in R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups selected from the group consisting of:

- a) -H;
- b) -Z-C₁₋₆ alkyl;
 -Z-aryl;
 -Z-C₁₋₆ alkylaryl;
 -Z-C₁₋₆-alkyl-NR₂₀R₂₁;
 -Z-C₁₋₆-alkyl-W-R₂₂;

wherein Z and W are independently selected from the group consisting of -CH₂-, -O-, -N(H)-, -S-, -SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,




wherein;

R₂₂, R₂₃, and R₂₄ are independently selected from the group consisting of aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl;

- c) halogen, hydroxyl, cyano, and carbamoyl, ~~and carboxyl~~; and

wherein R_{20} and R_{21} are independently selected from the group consisting of hydrogen, aryl, C_1 - C_6 alkyl, C_1 - C_6 alkylaryl, C_1 - C_6 alkoxy, and C_1 - C_6 alkoxyaryl; or

R_{20} and R_{21} are taken together to form a ring having the formula $-(CH_2)_q-X-(CH_2)_r-$ bonded to the nitrogen atom to which R_{20} and R_{21} are attached wherein q and r are, independently, 1, 2, 3, or 4; X is a direct bond, $-CH_2-$, $-O-$, $-S-$, $-S(O_2)-$, $-C(O)-$, $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-O-C(O)-$, $-NHSO_2NH-$,



R_{25} and R_{26} are independently selected from the group consisting of hydrogen, aryl, C_1 - C_6 alkyl, and C_1 - C_6 alkylaryl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

3. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

4. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole Trihydrochloride.

5. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-3-butyl-6-(3-diethylamino-1-propoxy)benzimidazole.

6. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-butyl-6-(3-diethylamino-1-propoxy)benzimidazole.

7. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-6-(3-diethylamino-1-propoxy)benzimidazole.

8. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-6-(3-diethylamino-1-propoxy)benzimidazole.

9. (Previously Presented) The compound of claim 1, wherein the compound is 2-[2-(3-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

10. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Ethoxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

11. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-(4-Chloro)phenethoxy)phenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

12. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-(3-diethylamino-1-propyl)-5-(3-diethylamino-1-propoxy)benzimidazole.

13. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-ethyl-5-(3-diethylamino-1-propoxy)benzimidazole.

14. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-(3-diethylamino-1-propyl)-5-(3-diethylamino-1-propoxy)benzimidazole.

15. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-benzyl-5-(3-diethylamino-1-propoxy)benzimidazole.

16. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-benzyl-5-(3-diethylamino-1-propoxy)benzimidazole.

17. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-propyl-5-(3-diethylamino-1-propoxy)benzimidazole

18. (Previously Presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-propyl-5-(3-diethylamino-1-propoxy)benzimidazole.

19. (Original) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

20. (Original) The pharmaceutical composition of to claim 19, in the form of an oral dosage or parenteral dosage unit.

21. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

22. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

23. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

24. (Original) The pharmaceutical composition of claim 19, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

25. (Withdrawn) A method for the inhibition of the interaction of RAGE with its physiological ligands, which comprises administering to a subject in need thereof, at least one compound of Formula (I) as claimed in claim 1.

26. (Withdrawn) The method of claim 25, wherein the ligand(s) is(are) selected from advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β -amyloid and amphotericin.

27. (Withdrawn) A method for treating a disease state selected from the group consisting of acute and chronic inflammation, symptoms of diabetes, vascular permeability, nephropathy, atherosclerosis, retinopathy, Alzheimer's disease, erectile dysfunction, and tumor invasion and/or metastasis, which comprises administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formula (I) as claimed in claim 1.

28. (Withdrawn) A method of prevention and/or treatment of RAGE mediated human diseases comprising administration to a human in need thereof a therapeutically

effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a ligand to the RAGE receptor.

29. (Withdrawn) The method of claim 28, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

30. (Withdrawn) The method of claim 29, wherein said therapeutic agents are selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

31. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises acute and/or chronic inflammation.

32. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises abnormal vascular permeability.

33. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises nephropathy.

34. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises atherosclerosis.

35. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises retinopathy.

36. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises Alzheimer's disease.

37. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises erectile dysfunction.

38. (Withdrawn) The method of claim 28, wherein the RAGE mediated human disease comprises tumor invasion and/or metastasis.

39. (Previously Presented) The compound of claim 1, wherein R_4 is

- a) -aryl;
- b) -C₁₋₆ alkyl;
- c) -C₁₋₆ alkylaryl; or
- d) -C₁₋₆ alkoxyaryl.